Loading stock data…
TNDM
$14.77-0.71 (-4.59%)
Market ClosedLast close May 11
Tandem Diabetes Care, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tandem Diabetes Care, Inc. in the Healthcare sector is trading at $14.77. The stock is currently 50% below its 52-week high of $29.65, remaining 18.4% below its 200-day moving average. Technical signals show oversold RSI of 27 and bearish MACD signal, explaining why TNDM maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Oversold momentum (RSI 27) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$14.77
Potential Upside
5%
Whystock Fair Value$15.51
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus21 analysts
Buy
Mean target$31.00+109.9%
Range$20.00 – $55.00
Fundamentals
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.42B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.74
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-132.40%
Volume
Today's trading volume
3.36M
Recent News
TNDM Q1 Deep Dive: Margin Expansion and Pipeline Advances Amid Business Model Shift
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 5.5% year on year to $247.2 million. On the other hand, the company’s full-year revenue guidance of $543 million at the midpoint came in 49.5% below analysts’ estimates. Its GAAP loss of $0.30 per share was 32% above analysts’ consensus estimates.
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
A week ago, Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ) came out with a strong set of first-quarter numbers that could...
Tandem Diabetes Care Q1 Earnings Call Highlights
Tandem Diabetes Care (NASDAQ:TNDM) reported record first-quarter pump shipments and sales for 2026, while reaffirming its full-year outlook as the diabetes technology company advances a shift toward pharmacy-channel reimbursement, expands direct international operations and prepares several product
Company News for May 8, 2026
Companies in The News Are: MCFT,TNDM,ZTS,BDX
Tandem to file tubeless insulin pump with FDA this quarter
The new version of Tandem’s Mobi pump would be the diabetes technology company’s first tubeless device.